|
David Goldstein is an American human geneticist. He trained in theoretical population genetics at Stanford University (PhD 1994), where he worked with Marcus Feldman and Luca Cavalli Sforza. Goldstein is founding Director of the Institute for Genomic Medicine at the Columbia University Medical Center, Professor of Genetics and Development and directs the genomics core of (Epi4K ) and administrative cores of Epi4K with Dan Lowenstein and Sam Berkovic. == Research == Goldstein's primary research interests include human genetic diversity, the genetics of disease, and pharmacogenetics. The Goldstein group and collaborators have discovered a number of disease causing genes and syndromes, in particular in neurological and infectious diseases including: * The role of IL28B in response to treatment for Hepatitis C infection in collaboration with John McHutchison and others. * Identification of ATP1A3 as the gene responsible for Alternating Hemiplegia of Childhood in collaboration with Erin Heinzen and others. * Discovery of NGLY1 deficiency as a new syndrome in collaboration with Vandana Shashi, Anna Need, and others. * New genes for epileptic encephalopathies as part of the (Epi4K ) Consortium. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「David B. Goldstein (geneticist)」の詳細全文を読む スポンサード リンク
|